Exelixis, Inc. (ticker: EXEL, exchange: NASDAQ Global Market (.O))
News Release -
Exelixis Announces May 19 Webcast of Presentation at Banc of America Securities 2005 Healthcare Conference
SOUTH SAN FRANCISCO, Calif., May 11 /PRNewswire-FirstCall/ -- Exelixis,
Inc. (Nasdaq: EXEL) announced today that Michael Morrissey, Ph.D., senior vice
president of discovery, will present at the Banc of America Securities 2005
Healthcare Conference at 11:20 a.m. (Pacific Time) on Thursday, May 19, 2005.
The presentation will be webcast and may be accessed in the Events page
under Investor Information on the Exelixis website at www.exelixis.com.
Exelixis, Inc. is a leading genomics-based drug discovery company
dedicated to the discovery and development of novel therapeutics across
various disease areas. The company is leveraging its fully integrated
gene-to-drug platform to fuel the growth of its proprietary drug pipeline.
Exelixis' development pipeline covers cancer and metabolism and is comprised
of the following compounds: XL119 (becatecarin), for which a multinational
Phase III clinical trial has been initiated in patients with bile duct tumors;
XL784, initially an anticancer compound, which completed a Phase I clinical
trial and is being developed as a treatment for renal disease; XL647, XL999
and XL880, anticancer compounds currently in Phase I clinical trials; XL820
and XL844 anticancer compounds for which investigational new drug (IND)
applications have been filed; and XL184, a potential IND candidate for the
treatment of cancer; and multiple compounds in preclinical development for
diseases including cancer and various metabolic and cardiovascular disorders.
Exelixis has established broad corporate alliances with major pharmaceutical
and biotechnology companies including GlaxoSmithKline (GSK) and Bristol-Myers
Squibb Company. Pursuant to a product development and commercialization
agreement between Exelixis and GSK, GSK has the option, after completion of
Phase IIa clinical trials, to elect to develop a certain number of compounds
in Exelixis' product pipeline, which may include the cancer compounds
identified in this press release (other than XL119), thus potentially
triggering milestone payments and royalties from GSK and co-promotion rights
by Exelixis. For more information, please visit the company's web site at
SOURCE Exelixis, Inc.
/CONTACT: Charles Butler, Associate Director, Corporate Communications of
Exelixis, Inc., +1-650-837-7277, or email@example.com/
/Web site: http://www.exelixis.com /
CO: Exelixis, Inc.
IN: MTC BIO HEA
SU: TDS CCA
-- SFW120 --
9901 05/11/2005 16:00 EDT http://www.prnewswire.com